Technavio has announced their latest analysis report on drug pipeline for sarcoidosis. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat sarcoidosis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180802005986/en/
Technavio has published a new report on the drug development pipeline for sarcoidosis, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Sarcoidosis: Market overview
Sarcoidosis, also known as the Besneir-Boeck-Schaumann disease, is an auto-aggressive systemic granulomatous disease that primarily affects the lungs. However, it can affect almost all the organs of the body. It is a rare disease due to which patches of red and swollen tissue called granulomas develop in the organs of the body. It usually affects the lungs and skin. As the disease progresses, small lumps called granulomas appear in affected tissues. In most of the cases, these granulomas disappear, either with or without treatment. The disease can appear suddenly and then disappear. In some cases, it can develop gradually and produce symptoms that can be seen during a person's lifetime.
According to a senior market research analyst at Technavio, "Researchers believe that the disease is caused by an abnormal immune response. In a healthy person, inflammation occurs as the cells of the body's immune system work together to protect an organ or tissue from intruders."
Sarcoidosis: Segmentation analysis
This pipeline analysis report segments the sarcoidosis market based on RoA (subcutaneous, oral, inhalation, and intravenous), therapeutic modality (small molecule, peptide, recombinant enzyme, monoclonal antibody, and fusion protein), and geographical segmentation (US, Netherlands, Germany, and Australia). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Based on therapeutic modality, more than 44% of the molecules that are being investigated for the treatment of sarcoidosis are small molecule.
Looking for more information on this market? Request a free sample report
Technavio's sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Regulatory Framework
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- RoA
- Therapeutic modality
- Geographical coverage
Recruitment Strategies
- Recruitment status
- Gender
- Age
Key Companies
- Type of players
- Company overview
Discontinued or Dormant Molecules
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180802005986/en/
Contacts:
Technavio Research
Jesse Maida
Media Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com
